Trials / Terminated
TerminatedNCT03506048
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Emory University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial studies how well lenvatinib works when given together with standard of care iodine I-131 in treating patients with radioactive iodine-sensitive differentiated thyroid cancer. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVE: I. To evaluate the efficacy of lenvatinib pretreatment along with radioactive iodine (RAI) in patients with previously treated RAI sensitive thyroid cancer. SECONDARY OBJECTIVES: I. To demonstrate the safety of the combination of lenvatinib and RAI in patients with Iodine sensitive differentiated thyroid carcinoma (DTC). II. To assess dynamic changes in established serum based biomarkers of DTC (thyroglobulin \[Tg\] and Tg antibody). III. To explore the utility of protein and genetic biomarkers to predict treatment efficacy. OUTLINE: Patients receive lenvatinib orally (PO) once daily (QD) for 8 weeks and up to 12 weeks in the absence of disease progression or unaccepted toxicity. Patients also receive iodine I-131 PO daily as standard of care. After completion of study treatment, patients are followed up within 6 weeks, every 3 months for 1 year, and then periodically thereafter.
Conditions
- Differentiated Thyroid Gland Carcinoma
- Thyroid Gland Follicular Carcinoma
- Thyroid Gland Papillary Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | Given orally once daily continuously |
Timeline
- Start date
- 2019-01-16
- Primary completion
- 2021-06-24
- Completion
- 2021-06-24
- First posted
- 2018-04-23
- Last updated
- 2022-11-10
- Results posted
- 2022-11-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03506048. Inclusion in this directory is not an endorsement.